Cipla Limited (CIPLA) — Board Meeting

📢 Key Event
Approval of new MD & GCEO and FY2026 financial results at AGM

🔄 What Changed
New MD appointed; revenue and EBITDA margin record highs; R&D spend up; cash reserves doubled

🔮 What's Next
FY2027 pipeline includes 12-15 new filings, 40-50 US submissions, and launches in respiratory, diabetes, and cardiology segments

💡 Investor Takeaway
Strong financial performance and pipeline growth support long-term value, but near-term margin pressure and US pricing risks require monitoring

Cipla held its 90th AGM on 25 June 2026, approving financial results, auditor appointments, and leadership changes, including Mr Achin Gupta as new MD & GCEO. The company reported record revenue of ₹28,000+ crores, 21% EBITDA margin, and 13.8% net profit margin, with India revenue growing 9% YoY. Key growth drivers include respiratory, diabetes, and specialty segments, supported by ₹1,970 crores R&D investment (7% of revenue). Sustainability milestones include 82% emission reduction and ₹11,000 crores cash reserves. Shareholders raised concerns on US pricing pressure, FY2027 outlook, and factory access, while management highlighted pipeline progress, including Tirzepatide and Semaglutide launches.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This